News NICE rejects BMS immunotherapy in advanced bladder cancer No review for three years after final guidance
News Fury as NHS rejects cystic fibrosis drug price offer It may be the 70th birthday of the NHS but this was no day of celebration for a group of patients with cystic fibrosis who have been told by officials there is no way forward in a pricing r
News Roche drug too pricey in progressive MS, says NICE Ocrevus is effective but too pricey in PPMS, says NICE
News Industry urges EU to scrap national HTA bodies Influential EU committee discusses proposals today
News NICE says 'no' to Roche's Perjeta after breast cancer surger... NICE consulting on first draft decision
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.